Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial

Diabetes, Obesity and Metabolism

Volumn 19, Issue 12, 2017, Pages 1805-1809

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Mantzoros, Christos S ^b   Polymerou, Vaia ^c   Katsinelos, Panagiotis ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Biomedicine SA   (Greece)

Author keywords

clinical trial; fatty liver; glucose metabolism; insulin resistance; liver; randomized trial; spironolactone; vitamin E

Indexed keywords

ADIPOCYTOKINE; ALPHA TOCOPHEROL; HOMOCYSTEINE; INSULIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 6; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; RETINOL BINDING PROTEIN 4; SPIRONOLACTONE; TUMOR NECROSIS FACTOR; VASPIN; BIOLOGICAL MARKER; MINERALOCORTICOID ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT;

ALANINE AMINOTRANSFERASE TO PLATELET RATIO INDEX; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEPATOBILIARY PARAMETERS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FIBROSIS; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; ADULT; BIOPSY; BLOOD; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; DIETARY SUPPLEMENT; ECHOGRAPHY; HYPERINSULINISM; INTENTION TO TREAT ANALYSIS; LIVER; LIVER CIRRHOSIS; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX;

ADIPOKINES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BIOPSY; COMBINED MODALITY THERAPY; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; LIVER; LIVER CIRRHOSIS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NON-ALCOHOLIC FATTY LIVER DISEASE; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; ULTRASONOGRAPHY; VITAMIN E;

EID: 85022337566     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12989     Document Type: Article

References (19)

1. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263-2273.
2. Mintziori G, Polyzos SA. Emerging and future therapies for nonalcoholic steatohepatitis in adults. Expert Opin Pharmacother. 2016;17(14):1937-1946.
3. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab. 2011;13(8):692-702.
4. Baldry EL, Aithal GP, Kaye P, et al. Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches. Diabetes Obes Metab. 2017. https://doi.org/10.1111/dom.12918. [Epub ahead of print].
5. Zhang HJ, Pan LL, Ma ZM, et al. Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study. Diabetes Obes Metab. 2017;19(2):284-289.
6. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012;46(4):272-284.
7. EASL–EASD–EASO. EASL-EASD-EASO Clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. 2016;59(6):1121-1140.
8. Pelusi S, Petta S, Rosso C, et al. Renin-angiotensin system inhibitors, type 2 diabetes and fibrosis progression: An observational study in patients with nonalcoholic fatty liver disease. PLoS One. 2016;11(9):e0163069.
9. Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab. 2010;12(5):365-383.
10. Wada T, Kenmochi H, Miyashita Y, et al. Spironolactone improves glucose and lipid metabolism by ameliorating hepatic steatosis and inflammation and suppressing enhanced gluconeogenesis induced by high-fat and high-fructose diet. Endocrinology. 2010;151(5):2040-2049.
11. Fujisawa G, Muto S, Okada K, Kusano E, Ishibashi S. Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats. Transl Res. 2006;148(3):149-156.
12. Wada T, Miyashita Y, Sasaki M, et al. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP-1c Tg mice fed high-fat and high-fructose diet. Am J Physiol Endocrinol Metab. 2013;305(11):E1415-E1425.
13. Pizarro M, Solis N, Quintero P, et al. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis. Liver Int. 2015;35(9):2129-2138.
14. Noguchi R, Yoshiji H, Ikenaka Y, et al. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats. Int J Mol Med. 2010;26(3):407-413.
15. Mitter SS, Shah SJ. Spironolactone for management of heart failure with preserved ejection fraction: Whither to after TOPCAT? Curr Atheroscler Rep. 2015;17(11):64.
16. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467-2474.
17. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.
18. Polyzos SA, Kountouras J, Zafeiriadou E, et al. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011;12(4):498-503.
19. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51(2):211-221.